# An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy

Study · id `cardio:ct-nct03279263` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03279263](<https://clinicaltrials.gov/study/NCT03279263>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03279263

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT03279263. Randomized; triple masking; primary purpose treatment. Start 2017-09-01 (actual); primary completion 2019-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT03279263, source copy `cardio:ctgov-nct03279263-2019-01-09`, retrieved 2026-10-26)
- Started: 2017-09-01 (actual) (ClinicalTrials.gov record NCT03279263, source copy `cardio:ctgov-nct03279263-2019-01-09`, retrieved 2026-10-26)
- Primary completion: 2019-09 (anticipated) (ClinicalTrials.gov record NCT03279263, source copy `cardio:ctgov-nct03279263-2019-01-09`, retrieved 2026-10-26)
- Completion: 2019-09 (anticipated) (ClinicalTrials.gov record NCT03279263, source copy `cardio:ctgov-nct03279263-2019-01-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03279263, source copy `cardio:ctgov-nct03279263-2019-01-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03279263-2019-01-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): MLR-1023
- Intervention (Other): Placebo
- Lead sponsor: Melior Pharmaceuticals
- Lead sponsor class: OTHER
- Collaborator: Bukwang Pharmaceutical, Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: cdf49624ce280ac9a457566e8d32329a14c950cbc00303a1479b68d84e02781e
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
